{"id":745325,"date":"2016-09-29T12:06:00","date_gmt":"2016-09-29T12:06:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/"},"modified":"2025-11-07T01:25:39","modified_gmt":"2025-11-07T06:25:39","slug":"merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/","title":{"rendered":"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness"},"content":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      commends the government of Guatemala on being the fourth country in<br \/>\n      Latin America to receive World Health Organization (WHO) verification of<br \/>\n      the elimination of river blindness (onchocerciasis). This announcement<br \/>\n      comes one year after the international coalition, formed by The Carter<br \/>\n      Center, the Pan American Health Organization (PAHO), WHO and Merck\u2019s<br \/>\n      MECTIZAN Donation Program, urged for the final push to eliminate<br \/>\n      onchocerciasis from the Americas.\n    <\/p>\n<p>\n      The government of Guatemala worked in partnership with the MECTIZAN<br \/>\n      Donation Program, PAHO, WHO and The Carter Center\u2019s Onchocerciasis<br \/>\n      Elimination Program for the Americas (OEPA), to eliminate onchocerciasis<br \/>\n      \u2013 one of the leading causes of preventable blindness worldwide \u2013 using<br \/>\n      MECTIZAN<sup>\u00ae<\/sup> (ivermectin), donated by Merck. With this<br \/>\n      verification, four of the six countries in the Americas historically<br \/>\n      at-risk for river blindness have verified elimination of the disease.\n    <\/p>\n<p>\n      \u201cWe celebrate this important achievement with the people of Guatemala.<br \/>\n      River blindness is a debilitating disease that affects individuals and<br \/>\n      their families, as well as the larger health care system and the<br \/>\n      economy,\u201d said Kenneth C. Frazier, chairman and chief executive officer<br \/>\n      of Merck. \u201cUntil river blindness is entirely eliminated around the<br \/>\n      world, we remain committed to working with our partners in the fight<br \/>\n      against this preventable disease.\u201d\n    <\/p>\n<p>\n      For more information, please read the following:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.paho.org%2Fhq%2Findex.php%3Foption%3Dcom_content%26view%3Darticle%26id%3D12520%253Aguatemala-eliminates-onchocerciasis-river-blindness%26Itemid%3D135%26lang%3Den&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=PAHO%2FWHO+Announcement&amp;index=1&amp;md5=21ffe3bd5715b482dede4b868a638afc\" rel=\"nofollow\">PAHO\/WHO<br \/>\n        Announcement<\/a>\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cartercenter.org%2Fhealth%2Friver_blindness%2Frb-press-releases.html&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=The+Carter+Center+Announcement&amp;index=2&amp;md5=50d1ec14829462a60a3585fd5c39fb7c\" rel=\"nofollow\">The<br \/>\n        Carter Center Announcement<\/a>\n      <\/li>\n<\/ul>\n<p>\n      <b>About the MECTIZAN Donation Program<\/b>\n    <\/p>\n<p>\n      In October 1987, Merck announced it would donate the medication MECTIZAN<br \/>\n      to all who need it for as long as necessary until river blindness is<br \/>\n      eliminated as a public health problem. The MECTIZAN Donation Program<br \/>\n      reaches more than 100 million people annually for river blindness. In<br \/>\n      Latin America, since 1989, more than 11 million treatments of donated<br \/>\n      MECTIZAN have been delivered by community health workers and<br \/>\n      non-governmental organizations. Learn more at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mectizan.org&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=www.mectizan.org&amp;index=3&amp;md5=ea4c8b1e8f97b3abcec9844f8dbf1369\" rel=\"nofollow\">www.mectizan.org<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=cf3d58a99776f23a7d5e3d9b4fa649dd\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=cded2d41627e4a2a058fa86c26c972ef\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=308a73c2fe58f9a34626db5c7841f637\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=9acc1b3353560e63109b7b29579b1ac4\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=4c24584f14a6aa3d025f01318622561e\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51430302&amp;newsitemid=20160929006148&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=4e402ea9e064b6394300d6ae3179221a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignl\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160929006148r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Lainie Keller, 908-236-5036     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, commends the government of Guatemala on being the fourth country in Latin America to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis). This announcement comes one year after the international coalition, formed by The Carter Center, the Pan American Health Organization (PAHO), WHO and Merck\u2019s MECTIZAN Donation Program, urged for the final push to eliminate onchocerciasis from the Americas. The government of Guatemala worked in partnership with the MECTIZAN Donation Program, PAHO, WHO and The Carter Center\u2019s Onchocerciasis Elimination Program for the Americas (OEPA), to eliminate onchocerciasis \u2013 one of the leading causes of preventable blindness worldwide \u2013 using MECTIZAN\u00ae (ivermectin), donated by Merck. With this verification, four of the six countries in the Americas historically at-risk for river blindness have verified elimination of the disease. \u201cWe<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,54,64,289],"class_list":["post-745325","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-corporate-responsibility-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, commends the government of Guatemala on being the fourth country in Latin America to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis). This announcement comes one year after the international coalition, formed by The Carter Center, the Pan American Health Organization (PAHO), WHO and Merck\u2019s MECTIZAN Donation Program, urged for the final push to eliminate onchocerciasis from the Americas. The government of Guatemala worked in partnership with the MECTIZAN Donation Program, PAHO, WHO and The Carter Center\u2019s Onchocerciasis Elimination Program for the Americas (OEPA), to eliminate onchocerciasis \u2013 one of the leading causes of preventable blindness worldwide \u2013 using MECTIZAN\u00ae (ivermectin), donated by Merck. With this verification, four of the six countries in the Americas historically at-risk for river blindness have verified elimination of the disease. \u201cWe\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\\\/\",\"name\":\"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-09-29T12:06:00+00:00\",\"dateModified\":\"2025-11-07T06:25:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/","og_locale":"en_US","og_type":"article","og_title":"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, commends the government of Guatemala on being the fourth country in Latin America to receive World Health Organization (WHO) verification of the elimination of river blindness (onchocerciasis). This announcement comes one year after the international coalition, formed by The Carter Center, the Pan American Health Organization (PAHO), WHO and Merck\u2019s MECTIZAN Donation Program, urged for the final push to eliminate onchocerciasis from the Americas. The government of Guatemala worked in partnership with the MECTIZAN Donation Program, PAHO, WHO and The Carter Center\u2019s Onchocerciasis Elimination Program for the Americas (OEPA), to eliminate onchocerciasis \u2013 one of the leading causes of preventable blindness worldwide \u2013 using MECTIZAN\u00ae (ivermectin), donated by Merck. With this verification, four of the six countries in the Americas historically at-risk for river blindness have verified elimination of the disease. \u201cWe","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:39+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/","name":"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-09-29T12:06:00+00:00","dateModified":"2025-11-07T06:25:39+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-congratulates-guatemala-as-fourth-country-in-latin-america-to-achieve-who-verification-of-elimination-of-river-blindness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Congratulates Guatemala as Fourth Country in Latin America to Achieve WHO Verification of Elimination of River Blindness"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9c27dd0b-4b61-4f14-9e7f-d6c39dec480c","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745325\/revisions"}],"predecessor-version":[{"id":3674732,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745325\/revisions\/3674732"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745325"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}